ERIC BENEVICH - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$1,516,512
Form type
4
Filing time
17 Feb 2026, 17:46:55 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BENEVICH ERIC Chief Commercial Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001643653

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,005 +3.8% $0.000000 54,760 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $133,194 -1,082 -2% $123.10 53,678 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +1,961 +3.7% $0.000000 55,639 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $131,319 -1,058 -1.9% $124.12 54,581 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,083 +3.8% $0.000000 56,664 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $139,511 -1,124 -2% $124.12 55,540 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +16,613 +30% $0.000000 72,153 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $1,112,488 -8,963 -12% $124.12 63,190 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,005 -25% $0.000000 6,017 12 Feb 2026 Common Stock 2,005 Direct F3, F4
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,961 -33% $0.000000 3,924 13 Feb 2026 Common Stock 1,961 Direct F3, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,083 -50% $0.000000 2,083 13 Feb 2026 Common Stock 2,083 Direct F3, F6
transaction NBIX Stock Option Award $0 +36,287 $0.000000 36,287 13 Feb 2026 Common Stock 36,287 $124.12 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +6,365 $0.000000 6,365 13 Feb 2026 Common Stock 6,365 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.